NESS

BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023

Retrieved on: 
Lundi, mai 8, 2023
International, NYSE, NESS, Pharmaceutical industry, Medical device

and NESS ZIONA, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Monday, May 15th, 2023, at 8:00 a.m.

Key Points: 
  • and NESS ZIONA, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Monday, May 15th, 2023, at 8:00 a.m.
  • ET, to report first quarter 2023 financial results and provide business updates.
  • To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International).
  • The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com .

BiomX Announces Second Closing of $7.5 Million Private Placement

Retrieved on: 
Vendredi, mai 5, 2023
OrbiMed, PIPE, Urinary tract infection, Cystic fibrosis, Sale, Patient, NESS, Cystic Fibrosis Foundation, SPA, NYSE American, Security (finance), NYSE, Pharmaceutical industry

and NESS ZIONA, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the second closing of its recently announced $7.5 million private placement (“PIPE”) investment.

Key Points: 
  • and NESS ZIONA, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the second closing of its recently announced $7.5 million private placement (“PIPE”) investment.
  • The second closing announced today was contingent upon approval of the issuance of the additional securities under the SPA by the Company's stockholders in accordance with NYSE American rules.
  • Pursuant to the SPA, at the second closing, the Company issued 24,632,243 shares of common stock (or common stock equivalents, the “Securities”) for gross proceeds of approximately $6 million, at a price of $0.245 per share.
  • BiomX and the investors have also entered into a Registration Rights Agreement pursuant to which BiomX has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the securities sold in the PIPE within 30 days following the second closing.

Newsight Imaging and Brightlaser Awarded Collaboration Grant to Develop Next Generation 3D Home and Industrial Security LiDAR

Retrieved on: 
Mercredi, mai 3, 2023
Education, Research and Technology Commission of the Islamic Consultative Assembly, Classification, Consulate, IIA, 3D, Innovation, Research, USD, Government, 2D, Lidar, Israel Innovation Authority, NESS, CMOS, Entrepreneurship, ITC, Transport, Security alarm, Creative industries, VCSEL

NESS ZIONA, Israel, May 03, 2023 (GLOBE NEWSWIRE) -- Newsight Imaging Ltd. (“Newsight”), a leading semiconductor innovator developing proprietary 3D machine vision sensors, spectral vision chips and systems, and Brightlaser Limited (“Brightlaser”), a global competitive supplier in VCSEL (vertical-cavity surface-emitting laser) technologies, today announced that Brightlaser has been awarded the first grant from the Hong Kong-Israel R&D Cooperation Programme to develop a next generation 3D home and industrial security LiDAR camera solution.

Key Points: 
  • After being introduced by the commercial attaché and the Consulate of Israel in Hong Kong & Macau, Newsight and Brightlaser partnered to apply for a grant to develop a next generation 3D home and industrial security LiDAR camera, based on Newsight Imaging’s eTOF™ proprietary patented technology and Brightlaser’s innovative solution for VCSEL.
  • “Their joint project uses LiDAR technology, commonly used for smart transportation purposes, for industrial and private security markets as well.
  • The 3D LiDAR Home Security market is currently a fraction of that, at roughly USD 305 Million, with the market demanding a robust shift towards LiDAR solutions.
  • 3D LiDAR Home Security Systems are set to grow much faster than the overall market, between 8% and 16% CAGR into 2030.

Newsight Imaging Launches MT LiDAR 3.1, a State-of-the-Art Reference Design for Accurate 3D Mapping for Robotics and Industrial Automation Markets

Retrieved on: 
Vendredi, avril 14, 2023
3D, Lidar, NESS, Hall, Architecture, Entrepreneurship, Robotics, B52, Family, Surveying, Hannover Messe

NESS ZIONA, Israel, April 14, 2023 (GLOBE NEWSWIRE) -- Newsight Imaging Ltd. (“Newsight”), a leading semiconductor innovator developing proprietary 3D machine vision sensors, spectral vision chips and systems, today announced the launch of a new member of the Multi-Triangulation (MT) LiDAR reference design family, the MT LiDAR 3.1 reference design.

Key Points: 
  • NESS ZIONA, Israel, April 14, 2023 (GLOBE NEWSWIRE) -- Newsight Imaging Ltd. (“Newsight”), a leading semiconductor innovator developing proprietary 3D machine vision sensors, spectral vision chips and systems, today announced the launch of a new member of the Multi-Triangulation (MT) LiDAR reference design family, the MT LiDAR 3.1 reference design.
  • Newsight’s MT LiDAR 3.1 reference design is now available for purchase.
  • Newsight will present the MT LiDAR 3.1 reference design at the Hannover Messe conference, at Hall 17, booth no.
  • “Utilizing our multi-triangulation technology specially designed for ultra-high accuracy for short-distance measurement applications, this new architecture will support solutions across robotics and industrial automation markets.

BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Mercredi, mars 29, 2023
Valencia CF Foundation, Workforce, International, Therapy, OrbiMed, PIPE, Clinical trial, Urinary tract infection, Pharmacokinetics, Atopic dermatitis, Cystic fibrosis, Part, CFU, Inflammatory bowel disease, Pseudomonas aeruginosa, Patient, NESS, Cystic Fibrosis Foundation, Disease, NYSE American, Security (finance), Mortality, Research, CF, NYSE, FEV1, Safety, Pharmaceutical industry, Medical imaging, Cryptocurrency

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • and NESS ZIONA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.
  • “BX004 not only demonstrated excellent safety, but also resulted in notable reductions in bacterial load in the lungs of CF patients.
  • We have already dosed patients in Part 2 of the Phase 1b/2a study and remain on track to report results in the third quarter of 2023.
  • BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for 2022.

BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023

Retrieved on: 
Lundi, mars 27, 2023
International, NYSE, NESS, Mobile phone, Medical device, Pharmaceutical industry

and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, March 29th, 2023, at 8:00 a.m.

Key Points: 
  • and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, March 29th, 2023, at 8:00 a.m.
  • ET, to report fourth quarter and full year 2022 financial results and provide business updates.
  • To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International).
  • The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com .

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Retrieved on: 
Lundi, mars 20, 2023
Dermatology, NESS, Rare-earth element, Pharmaceutical industry

NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright’s Autoimmune & Inflammatory Disease Virtual Event on Thursday, March 30, 2023.

Key Points: 
  • NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C. Wainwright’s Autoimmune & Inflammatory Disease Virtual Event on Thursday, March 30, 2023.

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Retrieved on: 
Vendredi, mars 10, 2023
Pharmacy benefit management, Nevoid basal-cell carcinoma syndrome, Acquisition, Martin PBM Mariner, EMA, Patient, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Psoriasis, Disease, American Academy of Dermatology, Food, Research, European Medical Association, Breakthrough, Sol–gel process, NDA, Rosacea, Orphan drug, NESS, Prescription, American Academy, Pharmaceutical industry, Cryptocurrency, Dermatology, IQVIA

Investigational compound SGT-610 has the potential to be the first-ever drug for treatment of Gorlin syndrome, if approved.

Key Points: 
  • Investigational compound SGT-610 has the potential to be the first-ever drug for treatment of Gorlin syndrome, if approved.
  • Prescribers reported positive experiences with TWYNEO (launched in April 2022), with the recurring base of prescribers increasing to a high of 82% in Q4 2022, from 66% in Q3 2022.
  • Only 6 months post its June 2022 launch, EPSOLAY captured the #2 branded topical position in rosacea in Q4 2022.
  • EPSOLAY’s recurring base of prescribers increased to 64% of its total prescribers in Q4 2022, from 22% in Q3 2022, showcasing sizeable post-trial adoption.

It Matters To You weighs in on revolutionary hydrogen fuel station proposed in Geelong

Retrieved on: 
Mercredi, mars 1, 2023
ELV, NESS, Transport, Renewable energy, CDC, Toll Group, Electrolysis, City, End of Life Vehicles Directive, Barwon Water, Hyundai ix35 FCEV, Sale, Hydrogen, Water, Recycling, Cleanaway

The new hydrogen-fuel station plans for Geelong will be revolutionary for the country as the push towards more sustainable and safe domestic fuel sources gains momentum.

Key Points: 
  • The new hydrogen-fuel station plans for Geelong will be revolutionary for the country as the push towards more sustainable and safe domestic fuel sources gains momentum.
  • The City of Geelong has advertised plans in recent weeks for the New Energies Service Station (NESS) which would be located on Refinery Road, Corio.
  • The NESS would fuel transportation vehicles such as trucks, buses, garbage collection vehicles and prime movers across the Geelong region, as major companies begin developing their hydrogen vehicle fleets.
  • To learn more about sustainability initiatives in the industry or to enquire about car removal Melbourne wide, visit It Matters To You online.

Enzymit Receives ISO 9001 Quality Management System Certification for Sustainable Enzyme Development

Retrieved on: 
Mardi, février 21, 2023
Organization, ISO 9001, Deep learning, ISO, International Organization for Standardization, Algorithm, Quality management system, Certification, Food, QMS, International Organization (journal), Drink, NESS, Enzyme, Doctor of Philosophy, Audit

NESS ZIONA, Israel, Feb. 21, 2023 /PRNewswire/ -- Enzymit, a bioproduction platform company developing cell-free enzymatic manufacturing technology, today announced it has been awarded International Organization for Standardization (ISO) 9001:2015 certification for its design of novel enzymes and enzymatic processes.

Key Points: 
  • ISO 9001 is the world's most recognized Quality Management System (QMS) standard, helping to ensure organizations meet the needs of their customers and other stakeholders more effectively.
  • This certification recognizes Enzymit's commitment to quality management and ensuring customer satisfaction.
  • "Enzymit has made concerted efforts to ensure that our proprietary development and manufacturing processes conform with the highest industry standards," said Gideon Lapidoth, PhD, CEO of Enzymit.
  • To achieve ISO 9001 certification, Enzymit was required to fulfill a range of criteria.